CRISPR Therapeutics (NasdaqGM:CRSP) recently announced the departure of Chief Operating Officer Julianne Bruno, reflecting a notable leadership change that could influence its operational direction.

The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.

With the citrus industry at a crossroads, growers are looking for any solution to cope with the deadly citrus greening ...

Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...

In a medical first, a research team in China has successfully stitched a CRISPR gene-edited pig liver into a brain-dead ...

Science is discovery and discovery evolve. Few discoveries have elicited as much excitement in the scientific world in recent times ...

Crispr Therapeutics said Chief Operating Officer Julianne Bruno would depart the company to pursue other opportunities, effective April 11. Bruno joined the gene-editing company in 2019 and stepped ...

Researchers from the J. Craig Venter Institute (JCVI), the Friedrich-Loeffler-Institut (FLI), and the International Livestock ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

A Peninsula biotech company raised $68 million from investors — including a venture philanthropy fund started by Lululemon ...

Focused on curing diseases like Alzheimer’s, Parkinson’s, and Huntington’s, Mammoth is advancing CRISPR beyond blood disorders to target the brain, muscle, and heart.